Immunitas Therapeutics

Immunitas Therapeutics is a biotechnology company focused on discovering and developing novel therapies for patients with cancer and autoimmune diseases. Their lead program, IMT-009, targets CD161 and is currently in clinical trials for patients with refractory tumors across multiple indications. The company's second program focuses on a novel therapeutic for autoimmune disease, leveraging their specialized understanding of the CD161-CLEC2D pathway. Immunitas is committed to developing highly differentiated immuno-oncology and autoimmune antibody-based therapeutics, showcasing a robust pipeline with a strong emphasis on innovation.

Immunitas boasts a team of highly renowned cancer research and therapeutic antibody pioneers, originally hailing from institutions like Dana Farber Cancer Institute, Mass General Cancer Center, the Broad Institute, and MIT. Their dedication to employee growth and success is evident in their competitive benefits package, which includes healthcare, paid time off, company-wide shutdowns, paid sabbaticals, tuition reimbursement, and paid parental leave. This commitment extends to internship and co-op programs, fostering a strong learning and growth experience for aspiring professionals.

Immunitas Therapeutics offers a 4-week paid sabbatical after 4 years of employment, as well as paid parental leave, which may be considered flexible benefits. They also provide a company-wide shutdown between Christmas and New Year's, indicating a possible period of collective time off. While the website doesn't explicitly mention remote work or flexible scheduling options, it does highlight a commitment to employee growth and success, which could indicate a willingness to discuss flexible work arrangements on a case-by-case basis.

Immunitas offers a competitive benefits package to its employees, including healthcare and paid time off. They also provide a company-wide shutdown between Christmas and New Years, a four-week paid sabbatical after four years of employment, $5,000 in tuition reimbursement for career development, and paid parental leave.

Immunitas Therapeutics is a biotechnology company committed to developing novel, differentiated therapeutics for patients with cancer and autoimmune diseases. They focus on targeting the CD161-CLEC2D pathway, with their lead program, IMT-009, currently in clinical trials for refractory tumors across various indications. The company builds upon its specialized knowledge of this pathway to develop therapies that aim to improve patient outcomes in areas of high unmet medical need.

Immunitas Therapeutics fosters a collaborative and proactive work environment that values the growth and success of its employees. The company seeks out individuals who are passionate about the pursuit of novel biology and are excited to contribute to a high-performing team.

Immunitas Therapeutics is committed to fostering a diverse, equitable, and inclusive workplace, prioritizing the growth and success of all employees. They actively seek collaborative and proactive team members, valuing a range of perspectives and backgrounds. Their commitment to diversity is evident in their employee benefits package, which includes paid parental leave, tuition reimbursement, and a company-wide shutdown between Christmas and New Years, allowing for a balanced and inclusive work-life environment.